hu.MAP 2.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: HuMAP2_02528
Confidence: Very High
Proteins| Genename | Protein Name | Links |
|---|---|---|
| EIF2B1 | Translation initiation factor eIF-2B subunit alpha (eIF-2B GDP-GTP exchange factor subunit alpha) | UniProt NCBI |
| EIF2B5 | Translation initiation factor eIF-2B subunit epsilon (eIF-2B GDP-GTP exchange factor subunit epsilon) | UniProt NCBI |
| EIF2B2 | Translation initiation factor eIF-2B subunit beta (S20I15) (S20III15) (eIF-2B GDP-GTP exchange factor subunit beta) | UniProt NCBI |
| EIF2B4 | Translation initiation factor eIF-2B subunit delta (eIF-2B GDP-GTP exchange factor subunit delta) | UniProt NCBI |
| EIF2B3 | Translation initiation factor eIF-2B subunit gamma (eIF-2B GDP-GTP exchange factor subunit gamma) | UniProt NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| CORUM:7292 | 1.21903689317e-17 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | EIF2B1-EIF2B2-EIF2B3-EIF2B4-EIF2B5 complex |
| HP:0031212 | 8.44528651762e-17 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal circulating progesterone level |
| HP:0008233 | 8.44528651762e-17 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Decreased circulating progesterone |
| HP:0004485 | 5.06717191057e-16 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Cessation of head growth |
| REAC:R-HSA-72731 | 1.37349689712e-15 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Recycling of eIF2:GDP |
| GO:0005851 | 4.91515675326e-14 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | eukaryotic translation initiation factor 2B complex |
| CORUM:7291 | 1.81514593393e-13 | 0.8 | EIF2B2 EIF2B4 EIF2B5 EIF2B3 | EIF2B2-EIF2B3-EIF2B4-EIF2B5 complex |
| HP:0008193 | 3.6889011509e-13 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Primary gonadal insufficiency |
| HP:0006808 | 5.2259432971e-13 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Cerebral hypomyelination |
| WP:WP107 | 1.28568364476e-11 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Translation Factors |
| HP:0000751 | 1.4349470775e-11 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Personality changes |
| HP:0007305 | 1.70067801777e-11 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | CNS demyelination |
| GO:0014003 | 3.57823411637e-11 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | oligodendrocyte development |
| HP:0000746 | 3.68127505717e-11 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Delusions |
| HP:0000869 | 4.86243282953e-11 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Secondary amenorrhea |
| HP:0003429 | 9.17164872043e-11 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | CNS hypomyelination |
| HP:0008209 | 1.61041817359e-10 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Premature ovarian insufficiency |
| HP:0031066 | 6.97571207635e-10 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal ovarian physiology |
| GO:0048709 | 8.05102676183e-10 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | oligodendrocyte differentiation |
| HP:0002171 | 2.03024823008e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Gliosis |
| HP:0003621 | 2.45203793086e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Juvenile onset |
| HP:0000786 | 2.94118098739e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Primary amenorrhea |
| REAC:R-HSA-72613 | 4.29128105718e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Eukaryotic Translation Initiation |
| REAC:R-HSA-72737 | 4.29128105718e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Cap-dependent Translation Initiation |
| KEGG:03013 | 5.10275915838e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | RNA transport |
| GO:0003743 | 6.13901440096e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | translation initiation factor activity |
| HP:0000712 | 7.39310896134e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Emotional lability |
| HP:0002354 | 7.39310896134e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Memory impairment |
| HP:0002317 | 7.76649830282e-09 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Unsteady gait |
| HP:0000141 | 1.35453518057e-08 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Amenorrhea |
| GO:0021782 | 1.56210562838e-08 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | glial cell development |
| HP:0100705 | 1.67886041391e-08 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the glial cells |
| HP:0005484 | 1.90145646213e-08 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Postnatal microcephaly |
| HP:0001254 | 2.7143326614e-08 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Lethargy |
| HP:0002352 | 3.52139335193e-08 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Leukoencephalopathy |
| HP:0000140 | 1.02882007181e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the menstrual cycle |
| GO:0008135 | 1.0665815608e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | translation factor activity, RNA binding |
| GO:0009749 | 1.14617719967e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to glucose |
| HP:0000858 | 1.18830076191e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Menstrual irregularities |
| HP:0011400 | 1.32962338082e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal CNS myelination |
| GO:0034284 | 1.41387678859e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to monosaccharide |
| GO:0009746 | 1.41387678859e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to hexose |
| HP:0000137 | 1.44418804682e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the ovary |
| GO:0010001 | 1.72940527637e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | glial cell differentiation |
| GO:0009743 | 2.23519505842e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to carbohydrate |
| GO:0090079 | 3.02690565276e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | translation regulator activity, nucleic acid binding |
| HP:0000618 | 3.62661688751e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Blindness |
| HP:0001945 | 3.62661688751e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Fever |
| REAC:R-HSA-72766 | 4.0494371971e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Translation |
| KEGG:05168 | 4.95116101375e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Herpes simplex virus 1 infection |
| GO:0042063 | 5.85912440409e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | gliogenesis |
| HP:0002376 | 7.88979794556e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Developmental regression |
| HP:0004372 | 9.72919433626e-07 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Reduced consciousness/confusion |
| GO:0045182 | 1.0026225265e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | translation regulator activity |
| HP:0004370 | 1.25502211093e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of temperature regulation |
| GO:0009408 | 1.3725553361e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to heat |
| HP:0003117 | 1.68176300273e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal circulating hormone level |
| HP:0040194 | 2.21741412062e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Increased head circumference |
| HP:0000256 | 2.21741412062e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Macrocephaly |
| GO:0009266 | 3.41575155137e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to temperature stimulus |
| HP:0007663 | 4.31471871984e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Reduced visual acuity |
| HP:0012447 | 4.94637357835e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal myelination |
| GO:0050852 | 5.18280243929e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | T cell receptor signaling pathway |
| GO:0005085 | 5.53769232154e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | guanyl-nucleotide exchange factor activity |
| HP:0001260 | 8.15341424622e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Dysarthria |
| GO:0006413 | 8.60332857394e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | translational initiation |
| HP:0000008 | 9.75811136636e-06 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of female internal genitalia |
| HP:0031466 | 1.2007171348e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Impairment in personality functioning |
| HP:0000812 | 1.40282580153e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal internal genitalia |
| GO:0050851 | 1.43956026192e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | antigen receptor-mediated signaling pathway |
| HP:0000648 | 1.56317495445e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Optic atrophy |
| HP:0010460 | 1.79320484724e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the female genitalia |
| HP:0410280 | 1.98794561094e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Pediatric onset |
| HP:0100543 | 2.33441059231e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Cognitive impairment |
| HP:0008373 | 2.67572717652e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Puberty and gonadal disorders |
| HP:0012795 | 2.70155465892e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the optic disc |
| GO:0043434 | 3.36079212321e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to peptide hormone |
| HP:0000587 | 6.09157696794e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the optic nerve |
| HP:0001257 | 7.32341005531e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Spasticity |
| GO:1901652 | 9.09038692953e-05 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to peptide |
| GO:0002429 | 0.000117480919 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | immune response-activating cell surface receptor signaling pathway |
| GO:0002768 | 0.000168660501172 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | immune response-regulating cell surface receptor signaling pathway |
| HP:0001288 | 0.000176106502064 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Gait disturbance |
| HP:0000505 | 0.000185597998937 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Visual impairment |
| HP:0001276 | 0.000186812645527 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Hypertonia |
| HP:0001290 | 0.00025774865947 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Generalized hypotonia |
| HP:0002167 | 0.000346759913439 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Neurological speech impairment |
| HP:0003674 | 0.000379919590475 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Onset |
| GO:0001541 | 0.000412725169389 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | ovarian follicle development |
| HP:0000252 | 0.000413265274216 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Microcephaly |
| HP:0040195 | 0.000422541364706 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Decreased head circumference |
| HP:0000504 | 0.000468905355505 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of vision |
| HP:0001098 | 0.000497552446818 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal fundus morphology |
| HP:0004329 | 0.000505603308587 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal posterior eye segment morphology |
| HP:0002493 | 0.000576829853785 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Upper motor neuron dysfunction |
| GO:0051020 | 0.000615904865263 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | GTPase binding |
| HP:0000818 | 0.000642670446673 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the endocrine system |
| HP:0012243 | 0.000754433222996 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal reproductive system morphology |
| GO:0002757 | 0.000781283109288 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | immune response-activating signal transduction |
| GO:0007417 | 0.000871111720657 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | central nervous system development |
| HP:0012337 | 0.000968762355884 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal homeostasis |
| HP:0007364 | 0.00101506212493 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Aplasia/Hypoplasia of the cerebrum |
| GO:0002764 | 0.0010152652871 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | immune response-regulating signaling pathway |
| HP:0000240 | 0.00125698530808 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of skull size |
| HP:0000078 | 0.00134320647188 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the genital system |
| GO:0009725 | 0.00158233933247 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to hormone |
| GO:0046545 | 0.00160515829483 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | development of primary female sexual characteristics |
| GO:0008585 | 0.00160515829483 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | female gonad development |
| GO:0002253 | 0.00161622147941 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | activation of immune response |
| HP:0000708 | 0.00193347598293 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Behavioral abnormality |
| HP:0031797 | 0.0020798868716 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Clinical course |
| HP:0002977 | 0.00229781396132 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Aplasia/Hypoplasia involving the central nervous system |
| HP:0001252 | 0.00230689622994 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Muscular hypotonia |
| GO:0006412 | 0.00235530637857 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | translation |
| GO:0046660 | 0.00265002518516 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | female sex differentiation |
| GO:0043043 | 0.00293652212837 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | peptide biosynthetic process |
| GO:0010243 | 0.00293652212837 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to organonitrogen compound |
| HP:0001250 | 0.00319095690486 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Seizures |
| HP:0011442 | 0.00363867481903 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of central motor function |
| HP:0002060 | 0.0037179458853 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the cerebrum |
| GO:0050778 | 0.00382718608595 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | positive regulation of immune response |
| REAC:R-HSA-392499 | 0.0039377533293 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Metabolism of proteins |
| HP:0100547 | 0.00395007677286 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of forebrain morphology |
| GO:1901698 | 0.00526420673272 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to nitrogen compound |
| HP:0003808 | 0.00557990536858 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal muscle tone |
| HP:0100022 | 0.00609587188076 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of movement |
| GO:0043604 | 0.00727283691478 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | amide biosynthetic process |
| GO:0006518 | 0.00744517222081 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | peptide metabolic process |
| HP:0000929 | 0.00794991423259 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal skull morphology |
| GO:0009628 | 0.0103710049276 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to abiotic stimulus |
| HP:0012372 | 0.0107492437093 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal eye morphology |
| HP:0012373 | 0.0120546885348 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal eye physiology |
| GO:0050776 | 0.012058619765 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | regulation of immune response |
| HP:0001939 | 0.0122264050876 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of metabolism/homeostasis |
| GO:0002684 | 0.0130263542754 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | positive regulation of immune system process |
| HP:0011804 | 0.0135213858544 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal muscle physiology |
| HP:0012443 | 0.0142087757286 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of brain morphology |
| HP:0000119 | 0.0146823604681 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the genitourinary system |
| HP:0009121 | 0.0166603503444 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormal axial skeleton morphology |
| HP:0011446 | 0.0183150212185 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of higher mental function |
| GO:0006417 | 0.0194326658217 | 0.8 | EIF2B2 EIF2B4 EIF2B1 EIF2B5 | regulation of translation |
| HP:0012759 | 0.0220185590621 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Neurodevelopmental abnormality |
| HP:0002011 | 0.0222964274548 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Morphological abnormality of the central nervous system |
| GO:0008406 | 0.022411068229 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | gonad development |
| GO:0042552 | 0.0237016209836 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | myelination |
| GO:0045137 | 0.0237016209836 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | development of primary sexual characteristics |
| GO:1901700 | 0.0254634614495 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | response to oxygen-containing compound |
| HP:0003011 | 0.0257924002128 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the musculature |
| GO:0007272 | 0.0264291737868 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | ensheathment of neurons |
| GO:0008366 | 0.0264291737868 | 0.6 | EIF2B2 EIF2B5 EIF2B4 | axon ensheathment |
| GO:0043603 | 0.0273795782463 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | cellular amide metabolic process |
| HP:0012639 | 0.0338634615703 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of nervous system morphology |
| GO:0022008 | 0.0340250107102 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | neurogenesis |
| HP:0000478 | 0.0345715487774 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the eye |
| HP:0011842 | 0.0361875215647 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of skeletal morphology |
| HP:0000007 | 0.0363523847838 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Autosomal recessive inheritance |
| GO:0034248 | 0.0371232263042 | 0.8 | EIF2B2 EIF2B4 EIF2B1 EIF2B5 | regulation of cellular amide metabolic process |
| GO:0006446 | 0.0412952841175 | 0.6 | EIF2B2 EIF2B1 EIF2B5 | regulation of translational initiation |
| HP:0000924 | 0.042794211029 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the skeletal system |
| HP:0000234 | 0.043361765796 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of the head |
| HP:0000152 | 0.0448070321906 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | Abnormality of head or neck |
| CORUM:0000000 | 0.0474603483533 | 1.0 | EIF2B4 EIF2B2 EIF2B3 EIF2B1 EIF2B5 | CORUM root |
Edges
| Protein 1 | Protein 2 | Score | Precision | Evidence |
|---|---|---|---|---|
| EIF2B3 | EIF2B4 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B2 | EIF2B5 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM boldt Malo fraction boldt_WMM |
| EIF2B2 | EIF2B3 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B2 | EIF2B4 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B2 | EIF2B1 | 1.0 | 0.949 | hein_WMM bioplex (EIF2B1,EIF2B2) bioplex_WMM boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B1 | EIF2B5 | 1.0 | 0.949 | bioplex (EIF2B1) bioplex_WMM boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B5 | EIF2B4 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B1 | EIF2B3 | 1.0 | 0.949 | bioplex (EIF2B1) bioplex_WMM boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B5 | EIF2B3 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B1 | EIF2B4 | 1.0 | 0.949 | bioplex (EIF2B1) bioplex_WMM boldt youn_WMM Malo fraction boldt_WMM |
Images
Click to enlarge
Complex HuMAP2_02528 has an average edge precision of 0.949 which is ranked 2 out of all 6965 complexes.
Related Complexes
| Genename | Complexes |
|---|---|
| EIF2B1 | HuMAP2_02528 HuMAP2_03847 HuMAP2_05332 |
| EIF2B5 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B2 | HuMAP2_00931 HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B4 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B3 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |